China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
2022 ESG Report Analysis | Yili: The Practical Path of ESG
Sep 28, 2023 09:01 PM
An Analysis of Domestic ESG Rating Agencies in China
Sep 28, 2023 12:46 PM
EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）
Sep 28, 2023 10:00 AM